Biotechnology in Japan

Brooks Life Sciences

The global leader in automated sample management for drug discovery and biostorage applications. Part of Brooks Automation (Nasdaq:BRKS) the Company provides unparalleled experience in automated compound, biological storage and sample processing solutions. Suppliers of the first automated, compound, DNA and also -80°C stores, Brooks understands the importance of sample integrity and provides a comprehensive range of solutions from ambient to -80°C. With the largest installed base, over 230 stores, Brooks’ systems manage over 1 billion samples worldwide. Complementary benchtop products for volume & precipitate detection, tube & vial handling, REMP, Matri & Aurora consumables are also available.

1001 to 5000 staff

Bgg

BGG is a global leader in the development and purification of high quality active natural plant ingredients for the dietary supplement, pharmaceutical, personal care, and food and beverage industries. Founded in 1995, BGG employs a staff of approximately 400, has 6 production sites, international branches in North America, Japan, China and Switzerland and manages sales in more than 70 countries. BGG selects raw materials, which are primarily from wild-crafted, organic, and from non-GMO sources, whenever possible. From these we produce health products and nutritional solutions that aid and enhance people's well-being and quality of life. Key products include: AstaZine®, Natural Astaxanthin from Haemattococus Pluvialis algae farmed in world’s First Organically Certified Astaxanthin Farm. ApplePhenon®, a patented highly concentrated natural polyphenol extract produced from wild unripe apples using proprietary technology. Applephenon®, supported by 16 clinical studies and more than 50 publication, has been clinically validated in 4 out of 5 of the typical risk factors for metabolic syndrome and in the prevention of seasonal allergies and sports endurance. TheraPrimeE®: BGG is one of the major worldwide producers of Tocotrienols extracted from Rice, Palm and Annatto that we offer in form of oils or water dispersible powders. MyrtiPRO®: Bilberry Extract from Wild Scandinavian bilberry fruit. ThinOGen®: Fucoxanthin, Thermogenic weight loss ingredient from seaweed. Licorice based products such as licorice powders and blocks, licorice flavonoids and licorice derivatives (monoammonium glycyrrhizinate, dipotassium glycyrrhizate, 18-β-glycyrrhetinic acid.). Steviol glycosides based products such as Reb A and D, managing the entire manufacturing process from raw material cultivation, extraction, compound isolation and finished product purification. BGG is ISO9001, and GMP certified.

201 to 500 staff

Tosoh Bioscience - Separation & Purification

The Separation and Purification group of Tosoh Bioscience, a division of Tosoh Corporation, is a major global supplier of chromatographic solutions predominately serving the pharmaceutical, biotechnology, and chemical industries. Since 1987, our product portfolio has expanded and evolved to anticipate industry demands and exceed our customers’ needs. Our comprehensive line of analytical HPLC columns, bulk process media resins, and dedicated GPC systems for polymer analysis, coupled with our expertise, make the solution to your separation and purification process clear. Tosoh Corporation, headquartered in Tokyo, Japan, is the parent of a global chemical and specialty materials group. All instruments, columns, and media sold by the Tosoh Bioscience Separations & Purification group are manufactured at Tosoh’s Nanyo Complex in Yamaguchi, Japan. Tosoh Bioscience Separations & Purification Group Facilities: • Tosoh Corporation, Bioscience Division – Japan • Tosoh Bioscience LLC – North and South America • Tosoh Bioscience GmbH – Europe, Middle East, Africa • Tosoh Bioscience Shanghai Co, Ltd. – China • Tosoh Asia, Pte. Ltd. – Southeast Asia • Tosoh India Pvt. Ltd. – India

501 to 1000 staff

Iktos

We are a leader in artificial intelligence and robotic solutions applied to research in medicinal chemistry and new drug design. Iktos' proprietary and innovative generative AI solution enables the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos has also developed Iktos Robotics, a unique AI-driven synthesis automation platform that dramatically accelerates the Design-Make-Test-Analyze cycle in drug discovery and is developing its own pipeline of drug candidates targeting oncology and auto-immune and inflammatory diseases. In March 2023, Iktos completed a 15.5M€ Series A financing round co-led by M Ventures and Debiopharm Innovation with contribution by Omnes Capital. In July 2024, Iktos announced the acquisition of Synsight, thereby complementing its Chemistry AI platform with a groundbreaking biology platform for the discovery of new drugs targeting Protein-Protein Interactions (PPI) and RNA-Protein Interactions (RPI). In 2025, Iktos was awarded a €2.5M grant from the European Innovation Council (EIC) Accelerator, with potential follow-on funding of €5M, to advance its integrated AI and robotics platform.

51 to 200 staff

Spiber Inc

Established in September 2007, Spiber is a biotech venture company based in Yamagata, Japan. We are dedicated to creating groundbreaking solutions that contribute to sustainable well-being. Driven by an unwavering commitment to building a world where everyone thrives, we develop innovative structural protein solutions, such as the Brewed Protein™ platform, a new material solution inspired by nature's diversity and circularity. By harnessing the power of precision fermentation, Spiber engineers proteins at the molecular level, resulting in versatile materials that can be tailored to specific needs. This innovative solution opens up new possibilities for sustainable and high-performance materials in various industries, including apparel, food, automotive, and more. We and our partners are constantly exploring diverse new applications for Brewed Protein™ materials in order to help pave the way for a brighter future. Our passion lies in fostering a circular economy, minimizing our environmental impact, and working together to build a world that is inclusive, fair, and regenerative. Brewed Protein™ fibers are now commercially available worldwide. Spiber's first mass production plant for protein polymer, located in Thailand, began operations in 2022. As production scales up, our distribution network is expanding to include brands, spinning companies, textile manufacturers, and fiber trading companies.

201 to 500 staff

Amino Up Co., Ltd

Bringing Smiles to the World through the Blessings of Nature We at Amino Up have made it our mission to ‘bring smiles to the world through the blessings of nature’. To this end, we do our best to deliver functional ingredients, made with local Hokkaido materials, to all four corners of the earth. From out very first product, Super Amino Up, to our most popular, AHCC, all of our products are of natural origin. These ‘blessings of nature’ form the roots of Amino Up. As a producer of functional ingredients, we are always looking towards the future and are passionately engaged in the research and development of new, innovative compounds. We also make providing proof of the safety and functionality of our ingredients our top priority, and are constantly conducting both basic and clinical research. The wealth of evidence we have gained allows us to manufacture trustworthy, safe products that we have complete faith in. We will continue to deliver safe, trustworthy, scientifically proven products, and strive to deliver on our position as a leading producer of functional ingredients worldwide.

51 to 200 staff

Bitbiome, Inc

bitBiome is a synthetic biology company built from their proprietary microbial single-cell microfluidic sequencing technology (bit-MAP). We have spent the last few years building up a large and diverse database (bit-GEM) of over 2 billion microbial sequences (adding additional sequences at a rate of nearly 1 billion per year). bit-GEM draws from many sources including human, animal, and over half coming from environmental samples including soil, seawater and hot springs. bit-GEM therefore offers a unique source of natural enzymes not found in any other private or public sequence library available. Combining bit-GEM with bioinformatics, protein structure analysis tools, and machine learning, we have developed bit-QED, an end-to-end enzyme discovery and development platform. bitBiome offers a range of services from single cell genomics, database screening and shortlisting, to wet lab evaluation of target sequences and directed evolution campaigns. We are also focused on conducting in-house R&D for applications in chemical, food and nutrition, and life science industries. Discover the full potential of microbes with bitBiome today!

11 to 50 staff

Kitazato

Kitazato Corporation is a global company based in Japan, dedicated to the assisted reproductive technologies field. Since our foundation in 1996, we’ve been researching, developing and manufacturing medical devices and media to support a wide range of fertility treatments. Thanks to our strong distribution network, we’re able to cooperate with IVF clinics all over the world. During the last two decades, thousands of IVF professionals have placed their trust in one of our largest contributions to the field, The Cryotop®Method, making it the undisputable market leader in cryopreservation of human gametes. One of our main pillars is to offer quality, environmentally friendly and constantly improving devices, in collaboration with scientists, as a way to secure access to the latest technologies. We’re committed to offering all-year-round training programs to clinical embryologists and gynecologists in order to expand their knowledge and enhance the benefits that our products offer in their everyday procedures. For more information

201 to 500 staff

Craif Inc

Craif is a molecular diagnostics company leveraging miRNA and machine learning for early cancer detection. Our proprietary platform, launched in Japan in 2022, powers the miSignal test, which screens for seven cancers (pancreatic, ovarian, esophageal, lung, breast, colorectal, and gastric) and has seen over 400% YoY revenue growth. In parallel with the commercialization of miSignal, we have started the clinical trial for the IVD test - pancreatic cancer diagnostic test for high risk population (e.g. diabetes, pancreatitis, etc.). This is a test seeking FDA/PMDA approval and planned to be reimbursed by insurance companies in the U.S. and reimbursed by the National Healthcare System in Japan. The clinical trial in Japan started in April 2024 and is planned to obtain approval in 2027H1. Craif USA was established in 2023 to bring this platform to the U.S. market, focusing on pancreatic cancer due to the high unmet need. We are currently enrolling cancers and high-risk controls to begin validation of the assay in a US population and are developing a US portfolio strategy that reflects the unmet clinical need and competitive landscape.

51 to 200 staff

Kintaro Cells Power International

Our aim at Kintaro Cells Power International is a medical supplier of "Kintaro Cells"- Human Bone Marrow Mesenchymal Stromal Cells. Our comapany's goal is to accumulate the most advanced bio-cultivation and medical technologies from around the world, create our own R&D and production laboratories, collaborate with international industry leaders, establish our own medical institutions, and develop innovative medical products. The 4 cornerstones of our business model: Automation of Cells Production Manufacture and supplier of Kintaro Cells Joint Research of BM-MSC development with Universities Education and Awareness

11 to 50 staff

Celaid Therapeutics

Celaid Therapeutics is a Japan-based biotechnology company, which has developed a platform technology to efficiently expand hematopoietic stem cells ex vivo without choosing its origins, including bone marrow, cord blood, or peripheral blood. By using the novel technology, we are developing a cell therapy product that brings HSC transplantation to the next level and helps patients with blood disorders. Our technology has many potential applications including gene/cell therapy that utilize gene editing on HSC. Our mission is to improve QOL of patients, their families, and HSC donors all over the world.

1 to 10 staff

Ac-Planta Inc

Ac-Planta Inc. is a RIKEN venture company founded on the basis of a technology discovered and patented at RIKEN,"Acetic acid strengthens plants' tolerance to dryness and high temperatures". The company currently develops, manufactures, and sells a biostimulant material (plant-activating agent) called "Skeepon" that strengthens plants' tolerance to drought and high temperatures. In recent years, global warming and climate change have caused many problems such as reduced crop yields and quality, and desertification, which in turn have caused food problems. At Aquaplanta Corporation, we aim to solve food and environmental problems around the world under our corporate philosophy of "Greenfulness - Surviving Climate Change Together". As a small, elite team, each person shares and understands the state of the company as a whole and its vision for the future, and has discretionary authority in their work. In addition, there is no separation between the business and research divisions, and through active exchange of information and discussion on a regular basis, we are always looking to further grow the business from each other's perspectives.

1 to 10 staff

Kiko Tech Co.,ltd

Since its establishment in 1974, KIKO TECH has been partnering with innovative companies worldwide to serve scientists in various fields. President Mr. Muneyoshi Mizuno leads a team of 90 dedicated professionals to provide analytical, medical and life science products to the scientific community in Japan. KIKO TECH is headquartered in Osaka, Japan, with regional offices in Tokyo, Tsukuba, and Kanagawa.

51 to 200 staff

Daisogel

Since the launch of DAISOGEL in 1992, we have always strived to provide our customers a family of lasting silica gel products with the quality and performance required for successful chromatographic purification of their life-saving and high-value therapeutics. We understand our customers’ expectations for us to provide the highest performance chromatographic silica gels with utmost quality control that are supplied and supported in a lasting, sustainable manner. This essence is captured in our Mission, Vision, and Values. The bonding type and bonding density varieties make different kinds of subgroups inside ODS or C8 modifications. Put together the different particle sizes and pore sizes with all the different kinds of chemical modifications the DAISOGEL® line-up stretches over several hundreds of catalogue products. Available Pore Sizes (µm) 60, 100, 120, 200, 300, & Available Particle Sizes (µm) Analytical Grades Ultra High Pressure:1.7 & 2.1 High Pressure: 2.5, 3, 4, 5 & 7 Preparative Grades High Pressure: 8, 10, 15 & 20 Medium Pressure: 30/50 & 40/60 Bare and Modified Silica Available Normal Phases: Chemically Bonded Phase SIL-P, APS-P, DIOL-P Reversed Phases: ODS-RPS, ODS-BP, ODS-BIO, C8/C4-P, C8/C4-BIO, C1-P, CN-P For further application information and to request a quote, please visit our website at

501 to 1000 staff

Prism Biolab Co., Ltd

PRISM BioLab is committed to maximizing the potential of its PepMetics™ Technology, transforming the “undruggable” to “druggable” with the aim of finding cures for the incurable. PRISM BioLab is a biotechnology company with PepMetics Technology, a proprietary drug discovery platform. PepMetics Molecules are designed to mimic α-helix or β-turn peptides using unique, stable scaffolds.

11 to 50 staff

Tokyo Future Style, Inc

Mission~ Tokyo Future Style, Inc. is a Japanese trading company in the field of bioscience. For the future of human being and the earth. Basic data~ Business Type: International trading company in the field of biomedical research field. Founding date: Jan. 2nd, 2007 Subsidiary: TFS Taiwan (Taiwan) Business outline~ Taking advantage of our network in the world, we are dealing in the various research products, materials and services related to state-of-art medical technology, such as regenerative medicine, cancer research, emerging- reemerging infectious disease field and so on. And we are also dealing in unique products and materials such as clinical specimens, nano-diamonds for imaging, Bioterrorism pathogen detection kits and others. One of our important business is marketing the novel and unique products and services developed by the venture companies and academia in the global market.

1 to 10 staff

Cosomil, Inc

Cosomil, Inc. is an innovative start-up dedicated to advancing early cancer detection through the development of blood-based tests. Our groundbreaking technology, known as Single Enzyme Activity-based Protein Profiling, enables ultra-sensitive detection of enzyme activity at the single molecule level using state-of-the-art fluorescent probes and microdevices.

1 to 10 staff

Kotai Biotechnologies, Inc

KOTAI Biotechnologies, Inc.(KOTAI, Osaka, Japan) is a spinout from Osaka University's world leading research center, Immunology Frontier Research Center launched in 2016. Our unique and sophisticated bioinformatics based on deep structure understandings has enabled us to analyze high throughput sequencing data of the immune systems such as Immune repertoire (BCR, TCR, antibodies, etc) and RNA-seq data. KOTAI is working on discoveries of new biomarkers and therapeutic compounds through the repertoire analysis.

11 to 50 staff

Epsilon Molecular Engineering Inc

Epsilon Molecular Engineering (EME) Inc. is an evolutionary molecular engineering based biopharmaceutical drug discovery company. EME was established in 2016 as a venture company from Saitama University in Japan, and has proprietary technologies, unique cDNA display libraries of the heavy chain single domain antibodies (VHH) and cyclic peptides with large diversity (10^13-14), and high-throughput screening methods using next-generation sequence, FACS and Machine learning (Bioinformatics). EME is, currently, conducting several joint research projects, including COVID-19, and 17 ongoing inhouse projects in the arias of cancer, inflammation, and Alzheimer’s disease, etc.

11 to 50 staff

Gra&green Inc

GRA & GREEN provides a one-stop gene editing solution for various plant species and cultivars. Creating gene-edited crops needs a delivery system suitable for each crop and cultivar."gene App", GRA & GREEN's gene-editing tool delivery platform, enables the rapid development of new crops from elite lines.

11 to 50 staff

Bex Co.,ltd

Manufacture of Electroporator in Japan. BEX Co, Ltd. is dedicated to designing, developing, manufacturing and marketing high-quality life science-related products for researchers. We'll keep contribute to innovation for cutting-edge research in life science. Featured product, CUI21EDITⅡis the best electroporator for in-vivo electroporation. We also provide biochemistry services. oligo DNA synthesis / peptide synthesis / RNA synthesis / STR analysis / Plasmid preperation etc.

11 to 50 staff

Nippi, Inc

Nippi, Inc. is highly regarded as the pioneer of collagen research for various applications, including foods, medical and pharmaceutical use, cosmetics, and health supplements. It is certain, however, that we will continue progressing on to the next stages, maintaining our “Quality First” policy and always envisioning possibilities of new opportunities for our business. Our history has always revolved around innovation and manufacture — high-quality leather, high-grade gelatin and collagen peptides, edible collagen casing, collagen cosmetics, chemically cross-linked PVC foam, MatriMix, and iMatrix-511 — all of these products are the proofs of our commitment to innovation and quality.

201 to 500 staff

Dioseve

Dioseve develops technologies to create fertilizable eggs from iPS cells / ES cells. By providing oocytes for couples who cannot give birth, we aim to establish unprecedented infertility treatment.

11 to 50 staff

Robotic Biology Institute Inc

RBI is located in Tokyo, Japan, to develop the technology platform to serve biological research experimentation by using the dual-arm humanoid robot.

11 to 50 staff

Biocom Systems, Inc

We can support R&D of transdermal and topical drug delivery and also evaluate percutaneous absorption of chemical compounds. We develop SKIN-CAD®, simulation software for skin pharmacokinetics of transdermal and topical drug delivery. SKIN-CAD® predicts the time courses of skin permeation, skin distribution and blood concentration under various modes of transdermal and topical delivery based on a combined model of skin diffusion layers and body compartments.

1 to 10 staff

Cytix Inc

7F Terada Bldg, 2-3-3 Shibakoen, Minato-ku, Tokyo, 105-011 JAPAN

11 to 50 staff

Morinaga Bioscience, Inc

Morinaga Institute of Biological Science, Inc.(MIoBS) is a member of Morinaga & Co, Ltd.(Morinaga group). We are focusing on developing the reagents for food safety and laboratory animals, utilizing immunoassay techniques as ELISA, Western blotting and Lateral Flow device. We are also responsible for analysis for food safety, quality control and hygiene assurance in Morinaga group. As a result of the recent increase in global interest in food allergies, regulations about the labeling of foods that contain allergens have been coming into effect in Japan since April 2001. Twenty-seven items3) have been designated for labeling and the Food Sanitation Act mandates that seven of those items (eggs, milk, wheat, buckwheat, peanut, shrimp, and crab) be listed in the ingredients. We used our exclusive immunoassay technology to begin selling ELISA kits for allergen testing (5 items) before the rest of the world in April 2002, and the kits were designated as official testing methods by the Japanese Ministry of Health, Labor, and Welfare in November of the same year. In 2005, we began selling FASPEK allergen testing kits that allow users to measure quantities in processed foods using an extract developed exclusively by MIoBS. That same year, the kits were designated as validated and accurate test kits by the Ministry of Health, Labor, and Welfare, and many Japanese public testing agencies, analysis agencies, and food companies use them to this day. Then, recognizing the sophistication of the technology, the Food and Drug Administration (FDA) designated the wheat kit5) as the official testing method for gluten-free foods.

51 to 200 staff

Nacalai Tesque, Inc

Nacalai Tesque is one of the leading life science reagent suppliers in Japan. Nacalai Tesque is a Manufacturer of HPLC and capillary columns, toxins, antibodies, enzymes, cell culture media, analytical kits, fine chemicals and research chemicals. Supplier to laboratories at universities, pharmaceutical and food-beverage companies, public and private research institutes, and to other Japanese trading houses. Importer / Distributor of products from the leading biochemical and life science companies. Exporter of its own COSMOSILR HPLC and capillary columns, separation kits, toxins, bio- reagents and fine chemicals. Recognized in the international research chemical and life science market Nacalai Tesque gears up its R&D and business activities for meeting the global demand in Biotechnology, Genomics, Proteomics, and Nanotechnology.

201 to 500 staff

Matrixome

Matrixome” is a novel term proposed by Professor Kiyotoshi Sekiguchi, at Osaka University. The term ‘matrixome’ is a subset of the proteome to define whole collections of extracellular matrix molecules that constitute the customized microenvironments of individual cell types. Under this concept, Matrixome, Inc. was established to conduct research on the matrixome and its applications.

11 to 50 staff

Iwai Chemicals Company Ltd

1 to 10 staff

On-Chip Biotechnologies Co., Ltd

On-chip® Sort On-chip® Droplet Generator On-chip® Droplet Selector On-chip® SPiS

11 to 50 staff

Liconic Japan

1 to 10 staff

Legacy Healthcare

Legacy Healthcare is a Swiss-based biopharmaceutical company focused on leveraging the pleiotropic activity and strong safety profile of plants to develop prescription botanical drugs that address serious medical conditions. Our first product candidate, CINAINU, has demonstrated strong safety and efficacy in patients suffering from alopecia areata, a chronic autoimmune condition with highly damaging psycho-social issues that impact all who suffer from it, especially children.

11 to 50 staff

Genefrontier Corp

11 to 50 staff

Institute For Advanced Biosciences, Keio University

We use cutting-edge biotechnologies to comprehensively measure and analyze human and micro-organic cellular activity, conduct computer analysis and simulation, and apply findings to medical, environmental, and food sciences. IAB is attracting attention from around the world as a pioneer in the new life sciences field that makes full use of IT in this way called Integrated Systems Biology.

11 to 50 staff

Photoq3 Inc

Biopharmaceuticals, including antibody drugs, have shown significant therapeutic effects, but they are not perfect. In addition, as the world’s super-aging society advances, there is an ever-increasing demand for treatments that are less burdensome on the body and preserve function. Based on our many years of experience and knowledge in the development of antibody drugs and phototherapy, we have searched for a treatment method that is less burdensome on the body and preserves function. As a result, we sucessfully established iTAP (intelligent Targeted Antibody Phototherapy) method. The iTAP method combines physical energy (light), biospecific binding (antibodies, peptides, etc.), and toxins to create a synergistic effect, and also makes it possible to control the extent of treatment and minimize side effects. PhotoQ3 was established in 2019 with the goal of “shedding new light on a world without a cure” based on the iTAP method, and is currently working to commercialize it as a new cancer treatment. The Company also possesses fundamental technologies such as protein expression technology and target discovery and quantification technology by proteogenomics, and aims to promote research and development not only in novel cancer drugs, but also in a wide range of other areas. To this end, we intend to actively promote collaboration with universities, medical institutions, research institutes, and other organizations, as well as joint relationships with pharmaceutical companies. We intend to continue our efforts to provide more optimal and advanced treatments for intractable diseases, especially cancer, and to realize medical care that enhances the quality of life, by making full use of our proprietary fundamental technologies.

1 to 10 staff

Takara Bio Inc

19791988PCRCDMO(Contract Development and Manufacturing Organization) Smiles in Life ※ X https://note.takara-bio.co.jp/x.com/Takara_Bio_JP Since 1979, Takara Bio has supported global life science research by providing innovative products and services. We were the first company to market genetic engineering research reagent (restriction enzyme) in Japan in 1979 and to introduce PCR system in 1988. Today, we offer approximately products for genetic and cell engineering research and provide high-quality, high-value-added genetic analysis services using Japan’s largest next-generation sequencers. We also serve as a CDMO (Contract Development and Manufacturing Organization) in regenerative medicine, cell therapy, and gene therapy fields, supporting pharmaceutical companies and biotech ventures worldwide. Takara Bio aims to bring “Smiles in Life” through biotechnology. This account focuses on product and service updates rather than recruitment information. Official X account (Japanese) https://note.takara-bio.co.jp/x.com/Takara_Bio_JP Global Network: Takara Bio Engineering (Dalian) Co, Ltd. Takara Korea Biomedical Inc. Takara Bio Medical Technology (Beijing) Co, Ltd. DSS Takara Bio India Pvt Ltd Takara Bio USA, Inc. Takara Bio Europe

1001 to 5000 staff

Phcbi Global

PHCbi Laboratory and Medical equipment is designed to meet the demands of the life science industries providing reliability, accuracy and usability of preservation, incubation and sterilization to facilitate cutting-edge research."PHCbi" is a new brand for our Life Science business that has globally supported research and healthcare over 50 years under previous brands. Since 1966, when we first launched pharmaceutical refrigerators in Japan, aiming to support advanced research in Life Science field, we have provided equipment and services required for sample preservation and bacterial / cell culture as well as maintenance of clean room environment. Our long history of manufacturing, sales, support and service excellence has earned us the respect of our customers throughout the world. We apply strict quality management in our global manufacturing system including the core manufacturing sites in Japan.

5001 to 10000 staff

In Silico Biology, Inc

ISB, in silico biology,inc, provides the series of software products which make it possible to simultaneously browse genome annotation, the analysis results of the large-scale tiling array and the next generation sequencer data, across the large genome sequence. These software products are already used in hundreds of the domestic universities and at the research institutes. These kinds of software technology are still rarely introduced in worldwide basis. Through the joint research with Nara Institute of Science and Technology and National Institute of Advanced Industrial Science and Technology and so on, ISB constantly implements such new generation technology and provides molecular biologists with the comprehensive analytical software tools.

1 to 10 staff

Syntheticgestalt

We are developing machine learning models for drug discovery and software for facilitating and automating research in the life-sciences industry.

11 to 50 staff

Nexuspiral Inc

1 to 10 staff

株式会社協和

No.1fracora

51 to 200 staff

Integriculture Inc.(インテグリカルチャー株式会社)

Integriculture Inc, a cellular agriculture platform company, develops sustainable protein, namely cell-based meat, and offers its production capability and technology to variety of clients wanting to develop products involving cell culture. Cell-based meat carries high hope as the holy grail to sustainable protein, for which $2T market is at stake. However, the production cost has been prohibitively high. Our patented “CulNet System” cultures cells 4~5 orders of magnitude less expensive to enable us to market cell-based meat at competitive prices. The system requires no externally added growth factors or serum, making it cleaner and safer compared to conventional meat, and even products by other cellular agriculture companies. The system in principle cultures any cells and produce anything produced by living things. Its astounding versatility makes it ideal for a general platform for clients wanting to produce food, cosmetics, supplements, functional ingredients, pharmaceuticals, and any other biological and agricultural products.

11 to 50 staff

セルソース株式会社

51 to 200 staff